Du B, Liu MY. Structure of the human P2Y 12 receptor in complex with an antithrombotic drug. Sci China Life Sci, 2014Sci, , 57: 645 -646, doi: 10.1007 After the 2012 Nobel Prize in Chemistry was awarded for the study of G-protein-coupled receptors (GPCRs), renewed interest was evident within the field. Purinergic P2Y receptors which belong to the group of metabotropic P2Y purinergic GPCRs stimulated by nucleotides, play crucial roles in inflammation, cancer and cardiovascular diseases. There are two distinct P2Y receptors for ADP expressed on platelets: the Gq-coupled P2Y 1 R and the Gi-coupled P2Y 12 R. Both contribute to collagen-induced platelet microparticle formation in whole blood and the formation of platelet-leukocyte aggregates. However, only P2Y 12 R is involved in the exposure of phosphatidylserine by thrombin or other platelet agonists [2] . P2Y 12 R (formerly SP1999) was discovered and identified as an ADP receptor with platelet clopidogrel sensitivity in 2001 [3] . Several generations of P2Y 12 R-targeted antithrombotic drugs have been developed because of its critical functional role in platelet aggregation. The first generation drugs, such as ticlopidine, clopidogrel and prasugrel, were prodrugs which needed to be metabolized before covalently binding to P2Y 12 R. Now newer drugs including ticagrelor, cangrelor and elinogrel that are either approved by the FDA or are still in clinical trials, directly act on P2Y 12 R. However, clinical studies have revealed certain limitations of these drugs including their long half-life and/or significant side effects. There is an unfulfilled medical need to develop new generation P2Y 12 R inhibitors, which was previously severely limited because of a lack of receptor structural and biochemical information.
After the 2012 Nobel Prize in Chemistry was awarded for the study of G-protein-coupled receptors (GPCRs), renewed interest was evident within the field. As seven-transmembrane (7TM) receptors with crucial physiological and pathological functions, GPCRs are the most popular drug targets known. In recent years, the Chinese government has funded several major projects on basic GPCR research and new drug discovery research targeting GPCRs through the National Basic Research Program (973 Program) and National Scientific and Technological Major Project for "Significant New Drugs Creation and Manufacturing Program". With the support from 973 Program (2012CB910400), Dr. Zhao Qiang's group from the Shanghai Institute of Materia Medica reported the high resolution (2.7 Å) crystal structure of P2Y 12 R in complex with a non-nucleotide reversible antagonist, AZD1283, in Nature [1]. Their findings provide the ground work for P2Y 12 R-based drug research and development.
Purinergic P2Y receptors which belong to the group of metabotropic P2Y purinergic GPCRs stimulated by nucleotides, play crucial roles in inflammation, cancer and cardiovascular diseases. There are two distinct P2Y receptors for ADP expressed on platelets: the Gq-coupled P2Y 1 R and the Gi-coupled P2Y 12 R. Both contribute to collagen-induced platelet microparticle formation in whole blood and the formation of platelet-leukocyte aggregates. However, only P2Y 12 R is involved in the exposure of phosphatidylserine by thrombin or other platelet agonists [2] . P2Y 12 R (formerly SP1999) was discovered and identified as an ADP receptor with platelet clopidogrel sensitivity in 2001 [3] . Several generations of P2Y 12 R-targeted antithrombotic drugs have been developed because of its critical functional role in platelet aggregation. The first generation drugs, such as ticlopidine, clopidogrel and prasugrel, were prodrugs which needed to be metabolized before covalently binding to P2Y 12 R. Now newer drugs including ticagrelor, cangrelor and elinogrel that are either approved by the FDA or are still in clinical trials, directly act on P2Y 12 R. However, clinical studies have revealed certain limitations of these drugs including their long half-life and/or significant side effects. There is an unfulfilled medical need to develop new generation P2Y 12 R inhibitors, which was previously severely limited because of a lack of receptor structural and biochemical information.
Dr. Zhao's group modified the protein sequence of the P2Y 12 R by inserting the thermostabilized apocytochrome b 562 RIL (BRIL) into the third intracellular loop region of the receptor, and incorporating a D294 xxY motif of the seventh transmembrane region to improve the protein yield and facilitate crystallization. The crystal structure of the antagonist AZD1283 (a novel P2Y 12 R antagonist developed for inhibition of artery thrombosis by AstraZeneca) bound to P2Y 12 R was solved for a crystal with C2 space group.
The P2Y 12 R structure contains the typical seven trans-membrane helices (as shown in Figure 1 ). Helix VIII in the C-terminal part is well resolved and is parallel to the lipid bilayer. The only observed disulfide bond is formed between C17 in the N-terminal part and C270 7.25 , while the conserved disulfide bond between C97 3.25 and C175 ECL2 is flexible and thus, was not modeled [4] . Two cholesterol molecules bound to each receptor are observed, suggesting the potential role of cholesterol in P2Y 12 R mediated signal transduction. When compared with those of other known GPCRs, the structures of the V and VI transmembrane helices are significantly different in P2Y 12 R [5] .
The AZD1283 binding pocket is composed of residues from helix III to helix VII. This pocket was previously only found in the GPCR PAR1. As both receptors (P2Y 12 R and PAR1) belong to the δ subgroup of GPCRs, this binding pocket may contain features that are common within the δ subgroup of GPCRs. A series of amino acid side chains in the helices are involved in polar and hydrophobic interac- tions with the ligand. The benzene ring of Y105 3.33 interacts with the nicotinate of AZD1283 via a π-π interaction, while it has a hydrophobic interaction with the piperidine group. The phenyl group of AZD1283 is accommodated by the hydrophobic pocket formed by F252 6.51 , R256 . Besides the AZD1283 binding site, there is another binding pocket observed in the crystal structure of P2Y 12 R, which is composed of helices I-III and VII. This is the first time that two different extracellular binding sites have been observed in a GPCR structure. Docking assays suggest that the AZD1283 binding pocket interacts with reversible ligands, while the other pocket may favor covalent small molecules. This indicates that an allosteric modification mechanism may play a role in regulating P2Y 12 R signaling. According to the docking analysis, C97 3.25 , which is thought to form a conserved disulfide bond with C175 ECL2 , is probably the covalent binding site of an active metabolite. This correlates well with the labile disulfide bond observed in the structure of P2Y 12 R; the active metabolites are reactive thiols, which would react with free cysteines rather than disulfides in the receptor. As P2Y 12 R is an important drug development target, its structure provides valuable insights for the development of improved P2Y 12 R antagonists. The unique conformation of the P2Y 12 R structure deepens our understanding of the ligand recognition elements of the purinergic receptor and the biological functions of GPCRs. Future structural studies of P2Y 12 R that build on the information described herein will support the design of new drugs with reduced side effects.
